Last year the Public Health Service of Amsterdam (GGD) started the Amsterdam PrEP project, a research project focused on the applicability of PrEP for HIV prevention among men who have sex with men (MSM) and transgender individuals. We now have a picture of the first 200 participants and of national developments over the past year. Almost three-quarters of participants preferred daily PrEP to event-based use (before and after sex). PrEP protected almost all participants from HIV. Two participants contracted an HIV infection in the past year.
(To read the press release in English, click the link on the right-hand side of the page).
17 hours ago | GGD Amsterdam
Last week, a report recommending PrEP for use in Scotland was endorsed by the Executive Leads Network, who govern Scotland's Sexual Health and Blood Borne Virus Framework. The report was written by the Scottish HIV PrEP Short Life Working Group (SLWG), administered by HIV Scotland and chaired by Dr Rak Nandwani.
19 hours ago | HIV Scotland
Norway has this week become the second country in Europe to make PrEP available, announcing that PrEP drugs will be available free of charge to at-risk groups via its National Health Scheme. According to HIV Norway, Minister for Health and Social Care Bent Høie announced the move, making Norway the first country in Europe to make the drug completely free for users (French users have to pay a small and largely reimbursible upfront fee.)
21 October 2016 | Pink News
NHS England is facing calls from leading HIV charities and a Conservative MP to explain why it heavily edited a press statement on a court ruling about an HIV prevention drug to include lines that have been described as “homophobic” and “irresponsible”.
21 October 2016 | BuzzFeed
A new report, PrEP Access in Europe, by the PrEP in Europe Initiative, a coalition of leading HIV organisations, calls on European governments and health authorities to make PrEP (pre-exposure prophylaxis) available to populations at imminent risk of HIV as a matter of urgency.
18 October 2016 | NAT press release
Gilead Sciences has begun a major trial to compare the efficacy of Descovy (emtricitabine/tenofovir alafenamide, or TAF) versus Truvada (tenofovir disoproxil fumarate, or TDF/emtricitabine) as pre-exposure prophylaxis (PrEP) against HIV.
14 October 2016 | Poz
Jim Pickett of the AIDS Foundation of Chicago: "PrEP has altered the landscape in HIV prevention in extraordinary and profound ways. It’s changing the lives of vulnerable individuals. It’s also bringing about big changes for the HIV workforce—health care providers, prevention specialists, outreach workers, social workers, educators and more. In fact, I believe we’ve entered the most dynamic period in our fight against HIV since 1996."
13 October 2016 | ETR
Want to find out more about PrEP, and if it’s right for you, but not sure where to get services? Researchers from the Rollins School of Public Health at Emory School of Public Health at Emory University recently published a searchable, online directory of PrEP providers across the United States.
13 October 2016 | BETA blog
The UK’s drug watchdog NICE has today released a review of HIV-preventing drugs amid a legal battle on the issue.
06 October 2016 | Pink News
Only four in 10 gay and bisexual men in Baltimore without HIV are aware that pre-exposure prophylaxis medication (PrEP) may significantly reduce their risk of contracting the virus, even those who had recently visited a doctor or been tested for a sexually transmitted disease, new Johns Hopkins Bloomberg School of Public Health research suggests.
05 October 2016 | Eurekalert Medicine & Health